secwatch.observer — SEC 8-K summary
======================================

Issuer:     Royalty Pharma plc (RPRX)
CIK:        0001802768
Form:       8-K
Filed at:   2023-02-15T23:59:59+00:00
Accession:  0001802768-23-000005
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Royalty Pharma Q4 Adj Cash Receipts up 96% YoY; guides FY23 $2.375-$2.475B excl. $475M milestone
--------------------------------------------------------------------------------

- Q4 2022 Adj Cash Receipts $1,064M (+96% YoY); FY 2022 $2,789M (+31%).
- Q4 GAAP operating cash flow $570M (+16% YoY); FY $2,144M (+6%).
- Announced transactions up to $3.5B in 2022, including $2.0B in upfront payments.
- FY 2023 guidance: Adj Cash Receipts $2,375M-$2,475M, underlying growth 4-9% prior to Biohaven payments; excludes potential $475M zavegepant milestone.
- In 2023, agreed to provide $500M upfront to Ionis Pharmaceuticals for a new partnership.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802768/000180276823000005/0001802768-23-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802768/000180276823000005/rprx-20230215.htm
  HTML page:      https://secwatch.observer/filing/0001802768-23-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer